Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine therapy for prostate cancer.

A I Sagalowsky

    Special Topics in Endocrinology and Metabolism
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Androgen deprivation therapy is a key treatment for metastatic prostate cancer, with new hormone analogs showing promise. Optimal timing and prediction of treatment response remain areas for further research.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?

    Cytopathology : official journal of the British Society for Clinical Cytology·2013
    Same author

    Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

    Urologic oncology·2011
    Same author

    Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study.

    Urologic oncology·2011
    Same author

    Treatment options for clinical stage 1 testis cancer.

    Proceedings (Baylor University. Medical Center)·2006
    Same author

    The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure.

    Cancer research·2001
    Same journal

    Alternative routes of peptide hormone administration.

    Special topics in endocrinology and metabolism·1985
    Same journal

    Clinical, endocrinologic, and biochemical effects of zinc deficiency.

    Special topics in endocrinology and metabolism·1985
    Same journal

    Hypothalamic hypogonadism.

    Special topics in endocrinology and metabolism·1985
    Same journal

    Pathogenesis and management of abnormal puberty.

    Special topics in endocrinology and metabolism·1985
    Same journal

    Prenatal diagnosis and management of endocrine and metabolic disorders.

    Special topics in endocrinology and metabolism·1985
    Same journal

    Ectopic hormones.

    Special topics in endocrinology and metabolism·1985
    See all related articles

    Area of Science:

    • Oncology
    • Urology

    Background:

    • Prostate cancer exhibits heterogeneity in androgen dependence between epithelial and stromal cells.
    • Androgen deprivation therapy (ADT) is a cornerstone for symptomatic metastatic prostate cancer, yielding high initial response rates.

    Purpose of the Study:

    • To evaluate the efficacy and safety of novel luteinizing hormone-releasing hormone (LH-RH) analogs for androgen deprivation in metastatic prostate cancer.
    • To compare LH-RH analogs with existing therapies like estrogen therapy and surgical castration.

    Main Methods:

    • Review of existing literature on ADT, surgical castration, estrogen therapy, and LH-RH analogs for metastatic prostate cancer.
    • Analysis of clinical outcomes, including response rates, survival data, and cardiovascular side effects.

    Related Experiment Videos

    Main Results:

    • Nearly 80% of patients with symptomatic metastatic prostate cancer respond to ADT.
    • LH-RH analogs demonstrate comparable efficacy to estrogen therapy at 2-year follow-up with significantly fewer cardiovascular side effects.
    • Surgical castration is effective, has low morbidity, and avoids compliance issues.

    Conclusions:

    • LH-RH analogs represent a promising alternative to estrogen therapy for medical androgen deprivation in metastatic prostate cancer.
    • The long-term survival benefit of ADT is not definitively established, and optimal initiation timing is debated.
    • Predictive techniques for androgen dependence are still under development for widespread clinical use.